Pediatric Weight-Loss Drug Prescriptions Rise

Why Are Weight-Loss Drug Prescriptions Rising Among Children?

Obesity affects about one in five U.S. children and adolescents, according to the Centers for Disease Control and Prevention. It is associated with a higher risk of type 2 diabetes, high blood pressure, abnormal cholesterol levels, fatty liver disease, sleep apnea and psychological distress. Greater recognition of these complications has encouraged earlier, more structured treatment rather than relying on watchful waiting.

The American Academy of Pediatrics recommends offering appropriately selected adolescents aged 12 years and older pharmacotherapy as an adjunct to intensive health behavior and lifestyle treatment. This shift, together with FDA authorization of medicines including semaglutide, liraglutide and extended-release phentermine-topiramate for certain adolescents, helps explain the reported growth in prescriptions. A rising prescription count, however, does not by itself establish how consistently patients take treatment or whether access and outcomes are equitable.

How Do Weight-Loss Medicines Work in Adolescents?

Semaglutide and liraglutide mimic glucagon-like peptide-1, or GLP-1, a hormone involved in appetite regulation, digestion and glucose control. Clinical trials have shown that GLP-1 medicines can produce clinically meaningful BMI reductions in adolescents with obesity when combined with behavioral support. Extended-release phentermine-topiramate affects appetite through different pathways, while orlistat reduces the amount of dietary fat absorbed by the intestine.

These treatments are not interchangeable, and none should be viewed as a stand-alone solution. Selection depends on age, obesity severity, related medical conditions, other medicines, contraindications and family preferences. Because weight commonly returns after medication is stopped, clinicians increasingly approach pharmacotherapy as part of long-term chronic-disease care while acknowledging that evidence about treatment extending from adolescence across many years remains limited.

What Safety Issues Should Families Discuss With a Clinician?

GLP-1 medicines commonly cause gastrointestinal effects such as nausea, vomiting, diarrhea, constipation and abdominal discomfort. Prescribing information also identifies less common but important concerns, including gallbladder disease and pancreatitis. Semaglutide and liraglutide carry boxed warnings concerning thyroid C-cell tumors observed in rodents and should not be used by people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.

Monitoring should include growth, pubertal development, nutritional adequacy, cardiometabolic health, adverse effects and emotional well-being. Clinicians should also screen for eating disorders, pregnancy where relevant and medicines or conditions that could affect treatment safety. Families should obtain these drugs through licensed prescribers and pharmacies because compounded or counterfeit products may not provide the same assurances of identity, strength and quality as FDA-approved medicines.